1. [Choroidal neovascularization secondary to pseudoxanthoma elasticum treated with ranibizumab: a report of 2 cases].
- Author
-
González-Gómez A, Morillo MJ, González-Escobar AB, and García-Campos JM
- Subjects
- Angiogenesis Inhibitors administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Choroidal Neovascularization etiology, Female, Fluorescein Angiography, Humans, Intravitreal Injections methods, Male, Middle Aged, Ranibizumab, Tomography, Optical Coherence, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Choroidal Neovascularization drug therapy, Pseudoxanthoma Elasticum complications
- Abstract
Case Report: We report 2 cases of pseudoxanthoma elasticum with angioid streaks and choroidal neovascularization (CNV) in both eyes. Intravitreal ranibizumab (Lucentis) was administered with successful results in both cases., Discussion: CNV has been reported to occur in 72% to 86% of patients with angioid streaks. Although uncommon, the impact of CNV is important because it tends to affect people of working age. Based on the effectiveness of ranibizumab in other secondary CNVs, we decided to use it in our patients, observing the functional and anatomical improvement., (Copyright © 2011 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF